Dr Alexander Lyon
Senior Lecturer and Honorary Consultant Cardiologist, Heart Failure Theme Lead, Cardiovascular Biomedical Research Unit
Dr Lyon is a consultant cardiologist and senior lecturer specialising in heart failure with a special interest in Takotsubo syndrome and cardiovascular diseases caused by cancer treatments known as Cardio-Oncology.
Training and experience
Dry Lyon studied medicine at Oxford University where he gained a first class degree, and studied for his PhD thesis in myocardial gene therapy at Imperial College London. he continued his gene therapy research during a postdoctoral research year int he laboratory of Roger Hajjar at Mount Sinair Hospital in New York.
Dr. Lyon was appointed to the board of the Heart Failure Association (HFA) of the European Society of Cardiology in 2016, and is the current chair of the HFA study groups for Cardio-Oncology and Takotsubo Syndrome. Dr. Lyon has published 106 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks and he is an associate editor of the European Journal of Heart Failure.
Clinical and Research Interests
Dr Lyon’s clinical interests are in the field of heart failure, cardio-oncology and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome, and the development of novel therapeutics including gene therapy for chronic heart failure. Dr Lyon also sees patients with a range of clinical problems including hypertneion, heart valve disease, coronary artery disease and cardiomyopathy . Dr lyon also specialises in the investigation of cardiac symptoms such as chest pain, breathlessness, palpitations (racing heart) dizzy spells and general cardiac health checks to guide risk factor management.
Dr Lyon is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Dr Lyon is the current president of the British Cardio-Oncology Society and he is the cardiology advisor to the charity Macmillan Cancer. He is a member of the International Cardio-Oncology Society and Dr Lyon was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.
Dr Lyon leads a research programme understanding the influence of stress and high catecholamine levels upon myocardial function, and he is coordinating both a national and European strategy to advance knowledge and improve care for individuals with Takotsubo syndrome. He runs a specialist clinic for patients with Takotsubo syndrome focusing on risk prediction and management of refractory symptoms.
Dr. Lyon is actively involved in clinical research and he was the theme leader for heart failure research in the NIHR-funded Biomedical Research Unit at the Royal Brompton Hospital (2012-2016). Dr. Lyon is UK lead investigator for the IDDEA-HF trial assessing a new mitochondrial therapy for acute heart failure, and Alex was the UK national lead investigator for two gene therapy trials for chronic heart failure (CUPID2 and SERCA-LVAD), which are the first gene therapy trials for heart failure in the UK. He is on the DSMC for several trials including the world’s first HIV gene therapy vaccine. Dr. Lyon was a co-PI for the RDT-PEF trial assessing the role of renal sympathetic denervation in patients with heart failure and preserved ejection fraction and Dr. Lyon is currently evaluating a new high resolution raspberry Pi multi camera system for remote monitoring of leg oedema in heart failure patients with Heartfelt Technologies.
Dr. Lyon also has an interest in cell and tissue therapies for heart failure and he is a co-investigator in the BHF Centre for Cardiovascular Regenerative Medicine at Imperial College.
Valerie, from Shropshire, came to Royal Brompton following a two year struggle with breathing difficulties. Read her story of how she finally got diagnosed.
Read More >>